help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Briasoulis, E.
Right arrow Articles by Pavlidis, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Briasoulis, E.
Right arrow Articles by Pavlidis, N.
The Oncologist, Vol. 2, No. 3, 142–152, June 1997
© 1997 AlphaMed Press

Cancer of Unknown Primary Origin

Evangelos Briasoulis, Nicholas Pavlidis

Department of Medicine/Oncology Unit, Ioannina University Hospital, Ioannina, Greece

Correspondence: Evangelos Briasoulis, M.D., Department of Medical Oncology, School of Medicine, University of Ioannina, Ioannina 45110, Greece. Telephone: +30-651-99394; Fax: +30-651-46618; e-mail: ebriasou{at}cc.uoi.gr

About 3% of all cancer patients suffer from cancer of unknown primary origin. These patients present with metastatic disease for which a primary site cannot be detected at the time of diagnosis. Sophisticated diagnostic techniques and operational procedures have failed to improve the diagnostic efficacy in this group of patients. Consequently, a limited diagnostic procedure with basic laboratory tests and imaging studies is sufficient for the diagnosis of this syndrome. The use of immunohistochemistry, as well as serum tumor markers of high specificity that may help to identify other tumors, is highly suggested. Although the prognosis for the majority of these patients still remains poor, several subsets of favorable outcome to treatment have been recognized. Nevertheless, promising in vitro data and new drugs on trials, paralleled with a better knowledge of the underlying pathogenetic molecular mechanisms, offer a more optimistic look to the future therapeutic management of these patients.

Key Words. Unknown primary • Unknown origin • Occult cancer • Carcinoma • Metastasis • Incidence • Diagnosis • Treatment




This article has been cited by other articles:


Home page
 Sci SignalHome page
H. Cheng, P. Liu, Z. C. Wang, L. Zou, S. Santiago, V. Garbitt, O. V. Gjoerup, J. D. Iglehart, A. Miron, A. L. Richardson, et al.
SIK1 Couples LKB1 to p53-Dependent Anoikis and Suppresses Metastasis
Sci. Signal., July 21, 2009; 2(80): ra35 - ra35.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. W. Tothill, A. Kowalczyk, D. Rischin, A. Bousioutas, I. Haviv, R. K. van Laar, P. M. Waring, J. Zalcberg, R. Ward, A. V. Biankin, et al.
An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin
Cancer Res., May 15, 2005; 65(10): 4031 - 4040.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Briasoulis, H. Kalofonos, D. Bafaloukos, E. Samantas, G. Fountzilas, N. Xiros, D. Skarlos, C. Christodoulou, P. Kosmidis, and N. Pavlidis
Carboplatin Plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group Study
J. Clin. Oncol., September 17, 2000; 18(17): 3101 - 3107.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1997 by AlphaMed Press.